|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
评价新生血管性年龄相关性黄斑变性(nAMD)患者玻璃体腔内注射Y400的安全性、耐受性、药代动力学和有效性的剂量递增多中心临床研究
[Translation] A multicenter dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of intravitreal Y400 in patients with neovascular age-related macular degeneration (nAMD)
Ⅰ期:
主要目的:评估nAMD受试者经单次或多次IVT注射Y400的安全性和耐受性,确定Y400的最大耐受剂量,并为2期研究推荐给药剂量(RP2D)。
次要目的: 评估nAMD受试者IVT单次和多次注射时Y400在全身的药代动力学特征(PK);评估nAMD受试者IVT单次和多次注射Y400的初步疗效。
探索目的:评估nAMD受试者IVT单次和多次注射Y400的免疫原性及其对Y400的PK、安全性的影响。
Ⅱ期:
主要目的:与阿柏西普比较,评价Y400经IVT注射治疗nAMD的有效性和安全性,为后期进一步临床研究提出最佳剂量与给药方案。
次要目的:评估Y400 IVT多次注射在全身的PK特征。
探索目的:评估Y400的免疫原性及其潜在影响;探索Y400血液浓度与疗效的相关性(量效关系)。
[Translation] Phase I:
Main purpose: To evaluate the safety and tolerability of Y400 administered by single or multiple IVT injections in subjects with nAMD, to determine the maximum tolerated dose of Y400, and to recommend a dosing dose (RP2D) for phase 2 studies.
Secondary objectives: To evaluate the systemic pharmacokinetics (PK) of Y400 in single and multiple IVT injections of nAMD subjects; to evaluate the preliminary efficacy of single and multiple IVT injections of Y400 in nAMD subjects.
Exploratory purpose: To evaluate the immunogenicity of single and multiple IVT injections of Y400 in subjects with nAMD and its impact on the PK and safety of Y400.
Phase II:
Main purpose: To evaluate the efficacy and safety of Y400 through IVT injection in the treatment of nAMD compared with aflibercept, and to propose the optimal dose and administration plan for further clinical research in the later stage.
Secondary objective: To evaluate the systemic PK profile of Y400 IVT multiple injections.
Exploration purposes: to evaluate the immunogenicity of Y400 and its potential impact; to explore the correlation between Y400 blood concentration and curative effect (dose-effect relationship).
100 Clinical Results associated with Shenzhen Kangzhe Weisheng Pharmaceutical Development Co., Ltd.
0 Patents (Medical) associated with Shenzhen Kangzhe Weisheng Pharmaceutical Development Co., Ltd.
100 Deals associated with Shenzhen Kangzhe Weisheng Pharmaceutical Development Co., Ltd.
100 Translational Medicine associated with Shenzhen Kangzhe Weisheng Pharmaceutical Development Co., Ltd.